APO RESEARCH · REPORT
Nanoparticle Drug Delivery Systems
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
Product & engineering
Understand the product.
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
Selected research
Industry Research
Nanoparticle Drug Delivery Systems Industry Research Report 2026
Market perspective
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
Read the full market overview
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
Global Nanoparticle Drug Delivery Systems key players include Gilead Sciences, CSPC, Pacira, Alnylam, etc. Global top four manufacturers hold a share about 37%.
Asia-Pacific is the largest market, with a share about 37%, followed by Europe, and North America, both have a share over 56 percent.
In terms of product, Liposomes Drugs is the largest segment, with a share over 92%. And in terms of application, the largest application is Retail Pharmacy, followed by Hospital, etc.
Report Scope
This report quantifies the global Nanoparticle Drug Delivery Systems market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nanoparticle Drug Delivery Systems.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nanoparticle Drug Delivery Systems Market by Company
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Nanoparticle Drug Delivery Systems Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Nanoparticle Drug Delivery Systems Segment by Application
Hospital
Retail Pharmacy
Other
Nanoparticle Drug Delivery Systems Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanoparticle Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nanoparticle Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanoparticle Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nanoparticle Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomes Drugs
- Lipid Nanoparticle Drugs
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Johnson & Johnson
- Sun Pharmaceutical
- CSPC
- Kinyond
- Teva
- Fudan-Zhangjiang
- Zydus Cadila
- TTY Biopharma
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Ipsen
- Sayre Therapeutics
- Jazz
- Alnylam
- Bausch Health
- Acrotech Biopharma
- Takeda
- Chiesi Farmaceutici
- Gilead Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nanoparticle Drug Delivery Systems by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liposomes Drugs
- 2.2.3 Lipid Nanoparticle Drugs
- 2.3 Nanoparticle Drug Delivery Systems by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Nanoparticle Drug Delivery Systems Breakdown Data by Type
- 3.1 Global Nanoparticle Drug Delivery Systems Historic Market Size by Type (2021-2026)
- 3.2 Global Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2027-2032)
4 Nanoparticle Drug Delivery Systems Breakdown Data by Application
- 4.1 Global Nanoparticle Drug Delivery Systems Historic Market Size by Application (2021-2026)
- 4.2 Global Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nanoparticle Drug Delivery Systems Market Perspective (2021-2032)
- 5.2 Global Nanoparticle Drug Delivery Systems Growth Trends by Region
- 5.2.1 Global Nanoparticle Drug Delivery Systems Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nanoparticle Drug Delivery Systems Historic Market Size by Region (2021-2026)
- 5.2.3 Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2027-2032)
- 5.3 Nanoparticle Drug Delivery Systems Market Dynamics
- 5.3.1 Nanoparticle Drug Delivery Systems Industry Trends
- 5.3.2 Nanoparticle Drug Delivery Systems Market Drivers
- 5.3.3 Nanoparticle Drug Delivery Systems Market Challenges
- 5.3.4 Nanoparticle Drug Delivery Systems Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nanoparticle Drug Delivery Systems Players by Revenue
- 6.1.1 Global Top Nanoparticle Drug Delivery Systems Players by Revenue (2021-2026)
- 6.1.2 Global Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2021-2026)
- 6.2 Global Nanoparticle Drug Delivery Systems Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nanoparticle Drug Delivery Systems Head Office and Area Served
- 6.4 Global Nanoparticle Drug Delivery Systems Players, Product Type & Application
- 6.5 Global Nanoparticle Drug Delivery Systems Manufacturers Established Date
- 6.6 Global Nanoparticle Drug Delivery Systems Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nanoparticle Drug Delivery Systems Market Size (2021-2032)
- 7.2 North America Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nanoparticle Drug Delivery Systems Market Size by Country (2021-2026)
- 7.4 North America Nanoparticle Drug Delivery Systems Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nanoparticle Drug Delivery Systems Market Size (2021-2032)
- 8.2 Europe Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nanoparticle Drug Delivery Systems Market Size by Country (2021-2026)
- 8.4 Europe Nanoparticle Drug Delivery Systems Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size (2021-2032)
- 9.2 Asia-Pacific Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nanoparticle Drug Delivery Systems Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nanoparticle Drug Delivery Systems Market Size (2021-2032)
- 10.2 South America Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nanoparticle Drug Delivery Systems Market Size by Country (2021-2026)
- 10.4 South America Nanoparticle Drug Delivery Systems Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size (2021-2032)
- 11.2 Middle East & Africa Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nanoparticle Drug Delivery Systems Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.1.4 Johnson & Johnson Nanoparticle Drug Delivery Systems Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Sun Pharmaceutical
- 12.2.1 Sun Pharmaceutical Company Information
- 12.2.2 Sun Pharmaceutical Business Overview
- 12.2.3 Sun Pharmaceutical Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.2.4 Sun Pharmaceutical Nanoparticle Drug Delivery Systems Product Portfolio
- 12.2.5 Sun Pharmaceutical Recent Developments
- 12.3 CSPC
- 12.3.1 CSPC Company Information
- 12.3.2 CSPC Business Overview
- 12.3.3 CSPC Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.3.4 CSPC Nanoparticle Drug Delivery Systems Product Portfolio
- 12.3.5 CSPC Recent Developments
- 12.4 Kinyond
- 12.4.1 Kinyond Company Information
- 12.4.2 Kinyond Business Overview
- 12.4.3 Kinyond Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.4.4 Kinyond Nanoparticle Drug Delivery Systems Product Portfolio
- 12.4.5 Kinyond Recent Developments
- 12.5 Teva
- 12.5.1 Teva Company Information
- 12.5.2 Teva Business Overview
- 12.5.3 Teva Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.5.4 Teva Nanoparticle Drug Delivery Systems Product Portfolio
- 12.5.5 Teva Recent Developments
- 12.6 Fudan-Zhangjiang
- 12.6.1 Fudan-Zhangjiang Company Information
- 12.6.2 Fudan-Zhangjiang Business Overview
- 12.6.3 Fudan-Zhangjiang Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.6.4 Fudan-Zhangjiang Nanoparticle Drug Delivery Systems Product Portfolio
- 12.6.5 Fudan-Zhangjiang Recent Developments
- 12.7 Zydus Cadila
- 12.7.1 Zydus Cadila Company Information
- 12.7.2 Zydus Cadila Business Overview
- 12.7.3 Zydus Cadila Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.7.4 Zydus Cadila Nanoparticle Drug Delivery Systems Product Portfolio
- 12.7.5 Zydus Cadila Recent Developments
- 12.8 TTY Biopharma
- 12.8.1 TTY Biopharma Company Information
- 12.8.2 TTY Biopharma Business Overview
- 12.8.3 TTY Biopharma Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.8.4 TTY Biopharma Nanoparticle Drug Delivery Systems Product Portfolio
- 12.8.5 TTY Biopharma Recent Developments
- 12.9 Pacira
- 12.9.1 Pacira Company Information
- 12.9.2 Pacira Business Overview
- 12.9.3 Pacira Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.9.4 Pacira Nanoparticle Drug Delivery Systems Product Portfolio
- 12.9.5 Pacira Recent Developments
- 12.10 Luye Pharma
- 12.10.1 Luye Pharma Company Information
- 12.10.2 Luye Pharma Business Overview
- 12.10.3 Luye Pharma Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.10.4 Luye Pharma Nanoparticle Drug Delivery Systems Product Portfolio
- 12.10.5 Luye Pharma Recent Developments
- 12.11 Leadiant Biosciences
- 12.11.1 Leadiant Biosciences Company Information
- 12.11.2 Leadiant Biosciences Business Overview
- 12.11.3 Leadiant Biosciences Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.11.4 Leadiant Biosciences Nanoparticle Drug Delivery Systems Product Portfolio
- 12.11.5 Leadiant Biosciences Recent Developments
- 12.12 Ipsen
- 12.12.1 Ipsen Company Information
- 12.12.2 Ipsen Business Overview
- 12.12.3 Ipsen Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.12.4 Ipsen Nanoparticle Drug Delivery Systems Product Portfolio
- 12.12.5 Ipsen Recent Developments
- 12.13 Sayre Therapeutics
- 12.13.1 Sayre Therapeutics Company Information
- 12.13.2 Sayre Therapeutics Business Overview
- 12.13.3 Sayre Therapeutics Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.13.4 Sayre Therapeutics Nanoparticle Drug Delivery Systems Product Portfolio
- 12.13.5 Sayre Therapeutics Recent Developments
- 12.14 Jazz
- 12.14.1 Jazz Company Information
- 12.14.2 Jazz Business Overview
- 12.14.3 Jazz Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.14.4 Jazz Nanoparticle Drug Delivery Systems Product Portfolio
- 12.14.5 Jazz Recent Developments
- 12.15 Alnylam
- 12.15.1 Alnylam Company Information
- 12.15.2 Alnylam Business Overview
- 12.15.3 Alnylam Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.15.4 Alnylam Nanoparticle Drug Delivery Systems Product Portfolio
- 12.15.5 Alnylam Recent Developments
- 12.16 Bausch Health
- 12.16.1 Bausch Health Company Information
- 12.16.2 Bausch Health Business Overview
- 12.16.3 Bausch Health Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.16.4 Bausch Health Nanoparticle Drug Delivery Systems Product Portfolio
- 12.16.5 Bausch Health Recent Developments
- 12.17 Acrotech Biopharma
- 12.17.1 Acrotech Biopharma Company Information
- 12.17.2 Acrotech Biopharma Business Overview
- 12.17.3 Acrotech Biopharma Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.17.4 Acrotech Biopharma Nanoparticle Drug Delivery Systems Product Portfolio
- 12.17.5 Acrotech Biopharma Recent Developments
- 12.18 Takeda
- 12.18.1 Takeda Company Information
- 12.18.2 Takeda Business Overview
- 12.18.3 Takeda Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.18.4 Takeda Nanoparticle Drug Delivery Systems Product Portfolio
- 12.18.5 Takeda Recent Developments
- 12.19 Chiesi Farmaceutici
- 12.19.1 Chiesi Farmaceutici Company Information
- 12.19.2 Chiesi Farmaceutici Business Overview
- 12.19.3 Chiesi Farmaceutici Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.19.4 Chiesi Farmaceutici Nanoparticle Drug Delivery Systems Product Portfolio
- 12.19.5 Chiesi Farmaceutici Recent Developments
- 12.20 Gilead Sciences
- 12.20.1 Gilead Sciences Company Information
- 12.20.2 Gilead Sciences Business Overview
- 12.20.3 Gilead Sciences Revenue in Nanoparticle Drug Delivery Systems Business (2021-2026)
- 12.20.4 Gilead Sciences Nanoparticle Drug Delivery Systems Product Portfolio
- 12.20.5 Gilead Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst